Calendula

Calendula officinalis exerts its primary pharmacological effects through flavonoids (notably quercetin at up to 532.7 mg/100g), triterpene glycosides (calendasaponins A–D), and carotenoids that collectively modulate oxidative stress pathways, suppress nitric oxide production, and upregulate endogenous antioxidant enzymes including glutathione and catalase. In preclinical studies, oral administration of calendula extract reduced macrophage superoxide production by 12.6–38.7% at doses of 100–250 mg/kg body weight, and flower extract achieved 50% DPPH radical scavenging at an IC50 of 100 µg/mL, supporting its documented role in wound healing and anti-inflammatory applications.

Origin & History

Calendula officinalis is native to the Mediterranean basin and southwestern Asia, with probable centers of domestication in southern Europe; despite being listed under a South American folk-use context, it is not indigenous to South America but has been widely naturalized and cultivated throughout Colombia and neighboring Andean nations following Spanish colonial introduction. The plant thrives in well-drained, moderately fertile soils under full sun at elevations ranging from sea level to approximately 2,500 meters, tolerating a wide temperature range from 5°C to 28°C. Commercial cultivation concentrates in Germany, Egypt, India, and parts of South America for pharmaceutical, cosmetic, and culinary markets, with flower heads harvested at full bloom to maximize carotenoid and flavonoid content.

Historical & Cultural Context

Calendula officinalis has been employed in European herbal medicine for over 900 years, documented as early as the 12th century in the writings of Hildegard von Bingen and referenced in medieval European herbals as a wound vulnerary and fever remedy under the name 'marigold.' In Colombian and broader Andean folk medicine, introduced during the 16th-century Spanish colonial period, the plant became embedded in local curanderismo traditions as 'caléndula,' used in poultices for skin infections, anti-inflammatory bath preparations, and gastrointestinal teas—the context for its listed primary use in this entry. Ancient Ayurvedic and Unani medical traditions recognized related Calendula preparations for their wound-healing and anti-inflammatory properties, and the plant was used extensively during the American Civil War and World War I as a field wound dressing when conventional supplies were limited. The genus name Calendula derives from the Latin 'calendae,' meaning the first day of the month, reflecting the plant's near-continuous flowering cycle across the calendar year, which contributed to its widespread availability and integration into traditional healing systems globally.

Health Benefits

- **Wound Healing and Skin Repair**: Triterpene glycosides (calendasaponins A–D) and lupeol promote tissue granulation and re-epithelialization; topical preparations have been used clinically in radiation dermatitis management, with calendula cream showing favorable tolerability compared to trolamine in pilot comparisons.
- **Anti-Inflammatory Activity**: Calendula extract suppresses nitric oxide (NO) production in a dose-dependent manner, achieving 50% inhibition at 147 µg/mL without cytotoxicity, attributed to triterpenoids and quercetin inhibiting inducible nitric oxide synthase (iNOS) pathways.
- **Antioxidant Protection**: Flower extract demonstrates broad radical-scavenging capacity with IC50 values of 100 µg/mL (DPPH), 6.5 µg/mL (ABTS), 480 µg/mL (hydroxyl radical), and 500 µg/mL (superoxide), with hydroalcoholic extracts yielding total phenolics of 123–217 mg GAE/100g.
- **Endogenous Antioxidant Enzyme Upregulation**: In vivo supplementation over one month elevated hepatic and blood glutathione and catalase levels, with modifications in glutathione reductase and peroxidase activity, suggesting systemic redox-regulatory effects beyond direct scavenging.
- **Antimicrobial Properties**: Essential oil and ethanolic extracts exhibit activity against a range of gram-positive bacteria and selected fungi, with caryophyllene (12.97% of terpene fraction) contributing to membrane-disrupting antimicrobial action relevant to wound-care applications.
- **Gastroprotective Effects**: Preclinical evidence indicates calendula extracts reduce gastric mucosal damage via anti-inflammatory and cytoprotective mechanisms, with calenduloside B implicated in modulating prostaglandin-related mucosal defense pathways.
- **Potential Antidiabetic Activity**: In vitro and animal studies suggest inhibition of α-glucosidase and α-amylase by flavonoids including isorhamnetin and quercetin, slowing postprandial glucose absorption, though human clinical validation is currently absent.

How It Works

Quercetin and isorhamnetin, the dominant flavonoids in Calendula officinalis, inhibit pro-inflammatory enzymes including cyclooxygenase-2 (COX-2) and lipoxygenase (LOX), and downregulate nuclear factor kappa-B (NF-κB) signaling, thereby reducing transcription of inflammatory cytokines such as TNF-α and IL-6. Triterpene glycosides—particularly calendasaponins A–D and calenduloglycoside variants—interact with cell membrane sterols, modulating membrane permeability and interfering with microbial adhesion while also stimulating fibroblast proliferation essential to wound closure. Carotenoids including β-carotene (97–637 µg/100g) function as singlet oxygen quenchers and contribute to the overall antioxidant milieu, while lupeol (9.45% of terpene fraction) has been associated with Nrf2 pathway activation, promoting transcription of phase-II detoxification and antioxidant enzymes such as heme oxygenase-1 (HO-1), glutathione-S-transferase, and catalase. Caryophyllene, a sesquiterpene comprising 12.97% of the volatile fraction, acts as a selective CB2 cannabinoid receptor agonist, contributing to peripheral anti-inflammatory and analgesic effects without central psychoactivity.

Scientific Research

The current evidence base for Calendula officinalis consists predominantly of in vitro phytochemical characterization studies and in vivo animal models, with limited well-powered human randomized controlled trials (RCTs); systematic searches identify only a small number of pilot-scale clinical investigations, mainly in topical wound care and radiation dermatitis. Preclinical in vivo studies demonstrate macrophage superoxide suppression of 12.6% at 100 mg/kg and 38.7% at 250 mg/kg body weight following oral administration, and one-month supplementation trials in animal models show measurable increases in hepatic glutathione and catalase. The most clinically cited human study compared topical calendula cream to trolamine for acute dermatitis in breast cancer patients undergoing radiotherapy (n=254 in one French RCT), where calendula was associated with reduced acute dermatitis frequency, though methodological heterogeneity limits generalizability. Overall, the evidence is preliminary to moderate: sufficient to support traditional topical applications with reasonable biological plausibility, but insufficient to establish definitive oral dosing guidelines, pharmacokinetic parameters, or systemic clinical efficacy in humans.

Clinical Summary

The most robust human clinical data for Calendula officinalis comes from a multicenter French RCT (Pommier et al., 2004; n=254) examining topical calendula ointment versus trolamine cream for prevention of acute radiation-induced dermatitis in breast cancer patients, which found a statistically significant reduction in Grade 2 or higher dermatitis (41% vs. 63%, p<0.001) and greater patient-reported pain reduction in the calendula arm. Smaller pilot trials and case series support wound-healing and anti-inflammatory effects in surgical and dermatological contexts, but sample sizes are typically under 50 participants and controls are often inadequate. No well-powered RCTs have evaluated oral calendula supplementation for systemic anti-inflammatory, antidiabetic, or antioxidant endpoints in humans, meaning extrapolation from animal data carries significant uncertainty. Confidence in topical wound-healing and dermatitis applications is moderate (supported by one adequately powered RCT), while confidence in all oral systemic applications remains low, warranting further investigation.

Nutritional Profile

Calendula officinalis leaves contain notable concentrations of vitamin B1 (thiamine: 67.3 mg/100g dry weight) and vitamin PP (niacin: 21.2 mg/100g dry weight), representing pharmacologically relevant rather than typical dietary nutrient levels at normal consumption quantities. The dominant phytochemical fraction includes quercetin (532.7 mg/100g), apigenin (15.9 mg/100g), isorhamnetin, and narcissin among flavonoids; triterpene glycosides including calendasaponins A–D and multiple calenduloglycoside variants; and carotenoids (β-carotene: 97–637 µg/100g depending on extraction method and tissue type). The sesquiterpene fraction of the essential oil is led by caryophyllene (12.97%), with additional sterols including stigmasterol (9.38%) and γ-sitosterol (5.07%) that may contribute to membrane-active and cholesterol-modulatory effects. Bioavailability of flavonoids from calendula is expected to follow general flavonoid pharmacokinetics—subject to intestinal conjugation, hepatic phase-II metabolism, and gut microbiome deglycosylation—with oral bioavailability of quercetin estimated at 24–50% depending on food matrix and formulation; specific bioavailability studies for calendula-derived phytochemicals in humans have not been published.

Preparation & Dosage

- **Topical Cream/Ointment (2–5% extract)**: The most clinically studied form; apply a thin layer to affected skin 2–3 times daily; standardized preparations typically contain 2–5% calendula flower extract as the active fraction.
- **Infused Oil (Macerate)**: Dried flower heads macerated in a carrier oil (olive, jojoba) at a 1:5 ratio (herb:oil) for 4–6 weeks; used topically for wound care and dry skin; no standardized concentration.
- **Hydroalcoholic Tincture (1:5, 50% ethanol)**: The hydroalcoholic (50:50 water:ethanol) extraction yields highest total phenolics (up to 217 mg GAE/100g); typical tincture dose is 1–4 mL three times daily in traditional Western herbalism, though human clinical dose-response data are absent.
- **Aqueous Infusion (Tea)**: 1–2 grams of dried flower heads steeped in 150 mL boiling water for 10 minutes; consumed 2–3 times daily in Colombian and European folk medicine for gastric and inflammatory complaints.
- **Standardized Dry Extract (Capsule, 20:1 concentration)**: Commercial supplements typically provide 250–500 mg per capsule; no clinically validated human dose established; animal studies used 100–250 mg/kg body weight (translates to approximately 1,100–2,750 mg/70 kg human equivalent, not yet confirmed in trials).
- **Standardization Note**: Quality preparations should be standardized to minimum 0.4% flavonoids (as quercetin equivalents) or minimum 5% total triterpenoids to ensure consistent bioactive delivery.

Synergy & Pairings

Calendula is frequently combined with chamomile (Matricaria chamomilla) in European phytotherapy for skin and mucosal applications, with both contributing complementary anti-inflammatory flavonoids (quercetin and apigenin from calendula; bisabolol and apigenin from chamomile) that synergistically inhibit COX and LOX pathways at lower individual doses than required when used alone. In Colombian traditional formulations, calendula is often paired with aloe vera (Aloe barbadensis) in topical wound preparations, where aloe polysaccharides (acemannan) support moist wound healing and immune modulation while calendula triterpenoids drive tissue granulation, a mechanistically complementary pairing. For oral antioxidant applications, combining calendula extract with vitamin C (ascorbic acid) may enhance carotenoid bioavailability and regenerate oxidized flavonoid intermediates through the ascorbate-quercetin redox cycle, a combination used in some European standardized phytomedicines.

Safety & Interactions

Calendula officinalis is generally regarded as safe for topical use at concentrations of 2–5%, with no documented systemic toxicity at these levels; the primary adverse reaction is contact allergic dermatitis, occurring in individuals sensitized to other members of the Asteraceae (Compositae) family—including ragweed (Ambrosia spp.), chrysanthemum, and arnica—due to shared sesquiterpene lactone allergens. Oral use at traditional herbal doses (1–4 mL tincture or 1–2 g dried herb daily) is considered low-risk in healthy adults based on longstanding traditional use, though formal human safety pharmacology studies are lacking; at higher doses extrapolated from animal studies, hepatic enzyme monitoring would be prudent. Theoretical drug interactions include additive sedation with CNS depressants due to mild sedative properties noted in some animal studies, potential additive hypoglycemic effects with antidiabetic medications based on in vitro α-glucosidase inhibition data, and possible enhancement of anticoagulant medications given quercetin's platelet-inhibitory properties, though clinically documented interaction reports in humans are absent. Calendula is contraindicated in pregnancy due to historical use as an emmenagogue and uterine stimulant, and should be avoided during lactation due to insufficient safety data; individuals with known Asteraceae allergies should avoid both topical and oral preparations.